Search

Your search keyword '"Chao, Hsing-Lung"' showing total 48 results
Start Over Author "Chao, Hsing-Lung"
48 results on '"Chao, Hsing-Lung"'

6. Skin Surface Dose for Whole Breast Radiotherapy Using Personalized Breast Holder: Comparison with Various Radiotherapy Techniques and Clinical Experiences

Author

Chen, Chiu-Ping, primary, Lin, Chi-Yeh, additional, Kuo, Chia-Chun, additional, Chen, Tung-Ho, additional, Lin, Shao-Chen, additional, Tseng, Kuo-Hsiung, additional, Cheng, Hao-Wen, additional, Chao, Hsing-Lung, additional, Yen, Sang-Hue, additional, Lin, Ruo-Yu, additional, Feng, Chen-Ju, additional, Lu, Long-Sheng, additional, Chiou, Jeng-Fong, additional, and Hsu, Shih-Ming, additional

Published
2022
Full Text
View/download PDF

10. Using computed tomography-based radiomics to predict outcomes for hepatocellular carcinoma patients receiving stereotactic body radiotherapy

Author

Chang, Hao-Chih, primary, Dai, Yang-Hong, additional, Shen, Po-Chien, additional, Chang, Wei-Chou, additional, Lo, Cheng-Hsiang, additional, Yang, Jen-Fu, additional, Lin, Chun-Shu, additional, Chao, Hsing-Lung, additional, Tu, Shu-Ju, additional, Huang, Wen-Yen, additional, and Hwang, Jing-Min, additional

Published
2021
Full Text
View/download PDF

15. Evaluation and prediction of therapeutic response for patients with hepatocellular carcinoma receiving stereotactic body radiotherapy using serial computed tomography scans and radiomics

Author

Dai, Yang-Hong, primary, Shen, Po-Chien, additional, Wang, Ying-Fu, additional, Chang, Wei-Chou, additional, Lo, Cheng-Hsiang, additional, Yang, Jen-Fu, additional, Lin, Chun-Shu, additional, Chao, Hsing-Lung, additional, Lu, Chieh-Sheng, additional, and Huang, Wen-Yen, additional

Published
2020
Full Text
View/download PDF

21. Review of current perspectives on low-energy X-ray intraoperative radiotherapy in early stage breast cancer

Author

Dai, Yang-Hong, primary, Chen, Yu-Jen, additional, Lin, Chun-Shu, additional, Lin, Kuen-Tze, additional, Huang, Wen-Yen, additional, Chen, Chang-Ming, additional, Su, Yu-Fu, additional, Fan, Chao-Yueh, additional, Lo, Chen-Hsiang, additional, Yang, Yen-Fu, additional, Tsao, Chih-Cheng, additional, Liu, Ming-Yueh, additional, Shen, Po-Chien, additional, Chao, Hsing-Lung, additional, and Chao, Kun-San, additional

Published
2019
Full Text
View/download PDF

23. Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer

Author

Chao Hsing-Lung, Chang Ying-Nan, Lin Yaoh-Shiang, Lin Chun-Shu, Su Yu-Fu, Chen Chang-Ming, Jen Yee-Min, Huang Wen-Yen, Lin Kuen-Tze, and Chang Li-Ping

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To analyze the rate of larynx preservation in patients of locally advanced hypopharyngeal cancer treated with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy, and compare the results with patients treated with primary surgery. Methods Between January 2003 and November 2007, 14 patients were treated with primary surgery and 33 patients were treated with concurrent chemoradiotherapy (CCRT) using IMRT technique. Survival rate, larynx preservation rate were calculated with the Kaplan-Meier method. Multivariate analysis was conducted for significant prognostic factors with Cox-regression method. Results The median follow-up was 19.4 months for all patients, and 25.8 months for those alive. The 5-year overall survival rate was 33% and 44% for primary surgery and definitive CCRT, respectively (p = 0.788). The 5-year functional larynx-preservation survival after IMRT was 40%. Acute toxicities were common, but usually tolerable. The rates of treatment-related mucositis (≥ grade 2) and pharyngitis (≥ grade 3) were higher in the CCRT group. For multivariate analysis, treatment response and cricoid cartilage invasion strongly correlated with survival. Conclusions IMRT plus concurrent chemotherapy may preserve the larynx without compromising survival. Further studies on new effective therapeutic agents are essential.

Published
2010
Full Text
View/download PDF

35. Multisession CyberKnife radiosurgery for post-surgical residual and recurrent pituitary adenoma: preliminary result from one center

Author

Chen, Yuan-Hao, Chang, Steven D., Ma, Hsin-I, Chou, Yu-Ching, Chao, Hsing-Lung, Jen, Yee-Min, and Ju, Da-Tong

Subjects
Clinical Investigation
Abstract

To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for patients with pituitary adenoma.We conducted a retrospective review of all patients treated by image-guided radiosurgery at our institution between August 2007 and June 2009. Twentytwo patients with pituitary adenoma were identified. The median follow-up period from date of treatment was 30.8 + 7.7months. The median patient age was 56 years. The mean tumor volume was 4.1 + 2.8 mL (range, 0.8-16.0 mL), and the prescribed dose was 25 Gy (5 Gy x 5).Tumors were treated with a mean coverage of 95.1 ± 1.3%(range 90.2-99.1%), a mean conformality index of 1.4 ± 0.4 (range, 1.2-1.8), and a mean treatment isodose line of 76.4 ± 3.0%(range70-83%). The primary endpoints were radiographic and endocrinological tumor control. The local radiographic control rate in this series was 100% (22/22). Radiographic evidence of tumor necrosis developed in 3 patients (13.7%).CyberKnife multisession radiosurgery of 25 Gy (5 Gy x 5) provided excellent local control with acceptable adverse effect in patients with pituitary adenoma post-transsphenoidal resection. This preliminary study provides data that supports the belief that the optic nerve and chiasm tolerate the above dosing regimens in perichiasmatic pituitary adenomas, and this dosing regimen may achieve satisfactory radiographic and endocrinological tumor control for post-transsphenoidal resection.

Published
2013

43. 18F-FDG PET and Combined 18F-FDG–Contrast CT Parameters as Predictors of Tumor Control for Hepatocellular Carcinoma After Stereotactic Ablative Radiotherapy

Author

Huang, Wen-Yen, primary, Kao, Chia-Hung, additional, Huang, Wen-Sheng, additional, Chen, Chang-Ming, additional, Chang, Li-Ping, additional, Lee, Meei-Shyuan, additional, Chao, Hsing-Lung, additional, Chiu, Chuang-Hsin, additional, Lo, Cheng-Hsiang, additional, and Jen, Yee-Min, additional

Published
2013
Full Text
View/download PDF

44. Stereotactic Ablative Radiotherapy for Patients with Unresectable or Medically Inoperable Cholangiocarcinoma

Author

Liu, Ming-Yueh, Lo, Cheng-Hsiang, Lin, Chun-Shu, Chao, Hsing-Lung, Yang, Jen-Fu, Lin, Kuen-Tze, Fan, Chao-Yueh, Su, Yu-Fu, and Huang, Wen-Yen

Abstract

Purpose The role of stereotactic ablative radiotherapy (SABR) in patients with unresectable or medically inoperable cholangiocarcinoma remains unclear. We examined the efficacy and safety of SABR in this group of patients.Methods From January 2008 to December 2014, 15 patients with 17 lesions were included in this study. The lesions included 14 intrahepatic, 1 hilar, and 2 distal bile duct tumors. Three patients were classified as medically inoperable because of old age or multiple comorbidities. Tumors measured 0.8-13 cm (median, 3.6 cm). The median prescribed dose was 45 Gy delivered in 5 fractions over 5 consecutive days.Results The median follow-up period for surviving patients was 29.9 months. Objective responses were observed for 10 of 17 tumors (58.8%), including 3 complete responses (17.6%). The median survival duration was 12.6 months, and the 1- and 2-year overall survival rates were 50.3% and 14.4%, respectively. The 1- and 2-year in-field failure-free rates were 61.5% and 30.8%, respectively. For patients with biologically effective doses (BEDs) exceeding 75 Gy10, the 1- and 2-year overall survival rates were 58.3% and 33.3%, respectively, compared to 20.0% and 0%, respectively for those with BEDs lower than 75 Gy10.Radiation-induced liver disease did not develop in any patient. Acute toxicities were generally mild and tolerable.Conclusions Stereotactic ablative radiotherapy could be an alternative treatment for unresectable or medically inoperable cholangiocarcinoma. Further dose escalation may be considered to optimize local control.

Published
2017
Full Text
View/download PDF

47. Novel application of stereotactic ablative radiotherapy using CyberKnife ® for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences.

Author

Lo CH, Huang WY, Chao HL, Lin KT, and Jen YM

Abstract

The treatment of renal cell carcinoma (RCC) in patients diagnosed with chronic kidney disease (CKD) requires particular care in order to preserve the remaining renal function. The present study aimed to investigate the potential of a novel nephron-sparing treatment, which is capable of targeting tumors embedded deep within tissues. The present study analyzed three patients, with pre-existing CKD and multiple comorbidities, who were successfully treated for stage I RCC using the CyberKnife ® stereotactic ablative radiotherapy (SABR) system. The total prescribed dose was 40 Gy in five fractions administered over five consecutive days. Treatment efficiency was determined using computed tomography scans of the tumors and periodic measurements of the glomerular filtration rate over a period of 12-40 months. Local control, defined as a radiologically stable condition, was achieved in all patients. Lung metastasis was observed in one patient nine months after SABR; however, the side-effects were generally mild and self-limiting. One patient developed renal failure 26 months after SABR, while the severity of CKD was only marginally altered in the other two patients and renal failure did not occur. In conclusion, in the present study, SABR with CyberKnife ® was observed to be well tolerated in the patients, with an acceptable acute toxicity effect. Therefore, it may represent a potential therapeutic option for patients with early-stage RCC who have previously been diagnosed with CKD, but for whom other nephron-sparing treatments are contraindicated.

Published
2014
Full Text
View/download PDF

48. Multisession CyberKnife radiosurgery for post-surgical residual and recurrent pituitary adenoma: preliminary result from one center.

Author

Chen YH, Chang SD, Ma HI, Chou YC, Chao HL, Jen YM, and Ju DT

Abstract

Objective: To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for patients with pituitary adenoma., Methods: We conducted a retrospective review of all patients treated by image-guided radiosurgery at our institution between August 2007 and June 2009. Twentytwo patients with pituitary adenoma were identified. The median follow-up period from date of treatment was 30.8 + 7.7months. The median patient age was 56 years. The mean tumor volume was 4.1 + 2.8 mL (range, 0.8-16.0 mL), and the prescribed dose was 25 Gy (5 Gy x 5)., Results: Tumors were treated with a mean coverage of 95.1 ± 1.3%(range 90.2-99.1%), a mean conformality index of 1.4 ± 0.4 (range, 1.2-1.8), and a mean treatment isodose line of 76.4 ± 3.0%(range70-83%). The primary endpoints were radiographic and endocrinological tumor control. The local radiographic control rate in this series was 100% (22/22). Radiographic evidence of tumor necrosis developed in 3 patients (13.7%)., Conclusion: CyberKnife multisession radiosurgery of 25 Gy (5 Gy x 5) provided excellent local control with acceptable adverse effect in patients with pituitary adenoma post-transsphenoidal resection. This preliminary study provides data that supports the belief that the optic nerve and chiasm tolerate the above dosing regimens in perichiasmatic pituitary adenomas, and this dosing regimen may achieve satisfactory radiographic and endocrinological tumor control for post-transsphenoidal resection.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results